CompletedPhase 1NCT04931147

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Redx Pharma Ltd
Principal Investigator
Annelize Koch
Simbec-Orion Clinical Pharmacology
Intervention
RXC007(drug)
Enrollment
90 enrolled
Eligibility
18-55 years · MALE
Timeline
2021 – 2023

Study locations (1)

Collaborators

Simbec Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04931147 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials